“Take care of your body. It’s the only place you have to live in.”

 

 

— Jim Rohn

PNA Medical Corner: Cabergoline Research

Dr. Marvin Bergsneider

This month the PNA Medical Corner spotlights a study co-authored by Dr. Marvin Bergsneider of UCLA, a member of the PNA. The study looks a the way
Cabergoline works to target tumors. They describe for the first time the role of CD8+ T cells following CBG-treatment.
Cabergoline Targets Multiple Pathways to Inhibit PRL Secretion and Increases Stromal Fibrosis.
Dongyun Zhang 1, Willy Hugo 1, Marvin Bergsneider 2, Marilene B Wang 3, Won Kim 2, Karam Han 4, Harry V Vinters 4, Anthony P Heaney 1 2

https://pubmed.ncbi.nlm.nih.gov/38781434/                                                      

Abstract

Objective: Unravel potential mechanism(s) of the on- and off-target actions of dopamine agonist therapy in both human prolactinoma tumor and neighboring stromal and immune cells.

Design and methods: Five surgically resected prolactinomas from 3 cabergoline (CBG)-treated and 2 treatment naive patients were analyzed by single cell RNA sequencing (scRNA-seq) to compare the cellular composition and transcriptional landscape.

Results: Six major cell populations that included tumor (88.2%), immune (5.6%), stromal (4.9%), progenitor cells (0.6%), proliferating cells (0.4%), and erythrocytes (0.2%) were observed. Tumor cells from CBG-treated patients expressed lower levels of genes that regulated hormone secretion, such as SCG2, VGF, TIMP1, NNAT, and CALD1, consistent with the inhibitory effects of CBG on hormone processing and secretion. Interestingly, we also observed an increased number of CD8+ T cells in the CBG-treated tissues. These cytotoxic CD8+ T cells expressed killing granule components, such as perforin and the granzymes GZMB, GNLY and KLRD1 as well as the inflammatory cytokine CCL5. Immune cell activation of these CD8+ T cells was further analyzed in a compartment-specific manner, and increased CD25 (IL2R) expression was noted in the CD8+ T cells from CBG-treated samples. Additionally, and confirming prior reports, we noted a higher stromal cell population in CBG-treated samples.

Conclusions: Our scRNAseq studies revealed key differences in the transcriptomic features of CBG-treated and untreated PRLomas in both tumor and microenvironment
cellular constituents, and for the first time describe previously unknown activation of CD8+ T cells following CBG-treatment which may play a role in the tumoricidal actions of CBG.

Keywords: Cabergoline; Pituitary tumor; Prolactinomas; Tumor Microenvironment; scRNAseq.
© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.

 

Giant pituitary adenomas need expert treatment

Giant pituitary adenomas pose special treatment challenges. Fortunately, advances in medical technology and understanding of the disease have greatly improved the management of these rare pituitary tumors. Experience and expertise are key to achieving the best possible results.

“The treatment options for giant pituitary adenomas have expanded,” says Mayo Clinic neurosurgeon Dr. Richard W. Byrne. “Several factors should be considered when planning treatment. A major multidisciplinary center can outline the best approach for each individual.”

Giant pituitary adenomas are tumors that measure more than 4 centimeters in diameter. Their size means they are often close to important nerves and blood vessels, which complicates surgical removal. Giant pituitary adenomas are also likelier than smaller tumors to cause symptoms such as vision and hormonal problems.

Surgery is the main treatment option. The goal is to improve hormonal and other symptoms while also preserving the pituitary’s function.

The minimally invasive procedure known as endoscopic transnasal transsphenoidal surgery is increasingly applied to giant pituitary adenomas. Mayo Clinic was among the first institutions to extensively research this approach.

“Endoscopic transnasal transphenoidal surgery is associated with lower postoperative complications and a higher likelihood of preserving normal pituitary and visual function. But the surgical team’s level of experience is critical,” Dr. Byrne says. “More-experienced surgeons have a better understanding of the practicalities of tumor removal because they are farther along on the learning curve.”

Tumors extending into certain brain regions generally require open surgery, or craniotomy. “There are several techniques for these open procedures, each of which has advantages and disadvantages,” Dr. Byrne says. Sometimes, open surgery is performed in combination with an endoscopic approach.

Some giant pituitary adenomas can be treated with medication. “A thorough presurgical evaluation can identify patients who might be able to avoid surgery,” Dr. Byrne says. “But it’s important to note that giant pituitary adenomas treated only with medication might need prolonged, annual imaging to detect recurrences.”

Due to their location, some giant pituitary adenomas are difficult to completely remove with surgery. Radiation therapy can be used to treat the remaining tumor. There are several options, including stereotactic radiosurgery, external beam radiation, intensity-modulated radiation therapy and proton beam therapy.

Identifying the best treatment for each individual requires a multidisciplinary team. “Collaboration among neurosurgeons, endocrinologists, and radiation oncologists is crucial for optimal patient care,” Dr. Byrne says.

Choosing the best approach for managing pituitary tumors

Some pituitary tumors don’t need treatment. They aren’t cancer, so if they don’t cause symptoms, monitoring them over time with regular imaging might be a good approach. But some pituitary tumors cause significant problems and require surgical removal.

Surgery is usually needed if the tumor is pressing on the optic nerves and limiting eyesight, if it’s causing headache or facial pain, or if it’s affecting hormone production,” explains Mayo Clinic neurosurgeon Dr. Chandan Krishna.

The best surgical approach depends on factors such as the tumor’s size, location and growth over time. It’s important to ask your health care provider which surgery is right for you, and to talk about the possible complications, risks and side effects. Surgical options include endoscopic transnasal transsphenoidal surgery, and craniotomy.

“With a transnasal endoscopic approach, we place a surgical instrument through the nostril to access the tumor. We then remove the tumor through the nose and sinuses,” Dr. Krishna says. “The surgery doesn’t need an incision and doesn’t affect other parts of the brain.” Mayo Clinic was among the first institutions to extensively research the endoscopic through-the-nose approach. Now standard practice, the procedure lowers discomfort and usually requires only an overnight stay in the hospital. At Mayo Clinic, ENT/head and neck surgeons work alongside neurosurgeons during these procedures.

Large pituitary tumors might be hard to remove through the nose — especially if the tumor has spread to nearby nerves, blood vessels or other parts of the brain. In those cases, a surgeon generally performs a craniotomy. A small cut is placed in the scalp, and the tumor is removed through the upper part of the skull.

“Both approaches to pituitary tumor removal are generally safe procedures,” Dr. Krishna says. “Complications are uncommon.”

Radiation therapy might be recommended if surgery isn’t feasible. Radiation therapy also might be used if a tumor isn’t completely removed with surgery or if a tumor comes back after surgery. There are several options, including stereotactic radiosurgery, external beam radiation, intensity-modulated radiation therapy and proton beam therapy.

Getting a second opinion or care at a major pituitary center helps ensure the best treatment for each individual. “No two patients are alike. No two pituitary tumors are alike,” Dr. Krishna says. “Experience and expertise in the full range of treatment approaches goes a long way towards providing the best outcomes.”

Featured News and Updates

News Articles June 2025

News Articles June 2025

New imaging tool to diagnose Cushing’s?

An article in Cushing’s Disease News looks at a study that find that a new form of PET scan, alongside a CT  scans can detect tumors that produce ACTH, common in Cushing’s disease. Read more:

https://cushingsdiseasenews.com/news/imaging-technique-found-accurately-id-cushings-pituitary-tumors/

Exercise and hormonal health

An article in mindbodygreen.com examines the effect of exercise on your hormones. Read more: https://www.mindbodygreen.com/articles/how-high-intensity-exercise-impacts-cortisol-and-other-hormones

Pituitary patient describes afterlife following near-death experience

A story on MSN.com relates the experiences of Brianna Lafferty, a pituitary patient who was clinically dead for 8 minutes. She now works as a transition guide. Read more here:

https://www.msn.com/en-us/health/medical/woman-who-died-for-8-minutes-claims-death-is-an-illusion-as-she-recalls-afterlife/ar-AA1FuWo5

Research Articles

June 2025 Research Articles

Pituitary Tumors

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0.

Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis.

Cardoso ABR, Zimmermann AC, Raverot G, Nunes-Nogueira VDS.Pituitary. 2025 Jun 2;28(3):70. doi: 10.1007/s11102-025-01541-0. 

Impulse control disorders in pituitary adenoma: What do we know and what we still don’t know in almost two decades?

Kadioglu P, Glezer A.Pituitary. 2025 Jun 2;28(3):71. doi: 10.1007/s11102-025-01533-0.

Clinico-pathological and molecular characteristics of pediatric-juvenile pituitary neuroendocrine tumors (PitNETs): A mono-institutional series.

Buccoliero AM, Giunti L, Ponticelli A, Innocenti L, Ricci F, Cetica V, Tirinnanzi B, Moscardi S, Stagi S, Sardi I, Mussa F, Genitori L, Scagnet M.Clin Neuropathol. 2025 Jun 2. doi: 10.5414/NP301685. Online ahead of print.

Pituitary Surgery


Use of a Septal Stapler to Secure a Septal Free Mucosal Graft to the Nasoseptal Flap Donor Site Following Endoscopic Endonasal Resection of a Pituitary Adenoma.

Miller JE, Fischer JL, Wang MB.J Neurol Surg Rep. 2025 Apr 23;86(2):e98. doi: 10.1055/a-2531-6140. eCollection 2025 Apr.

Hormonal health

The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.PMID: 40457737 No abstract available.

Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study.

Castro S, Ng Yin K, d’Aniello F, Alexander EC, Connolly E, Hughes C, Martin L, Prasad R, Storr HL, Willemsen RH, Dunkel L, Butler G, Howard SR.Hum Reprod Open. 2025 May 13;2025(2):hoaf026. doi: 10.1093/hropen/hoaf026. eCollection 2025.

Long-term pituitary function following transsphenoidal surgery for non-functional pituitary neuroendocrine tumor with apoplexy: a single-center retrospective analysis.

Zou D, Yang Y, Gao R, Ou Y, Luo J, Zhang Z, Yang T, Cheng J.Sci Rep. 2025 Jun 1;15(1):19226. doi: 10.1038/s41598-025-03053-0.

Safety and efficacy of endoscopic vs. microscopic approaches in pituitary adenoma surgery: A systematic review and meta-analysis.

Al-Dardery NM, Khaity A, Soliman Y, Ali MOM, Zedan EM, Muyasarah K, Elfakhrany MD.Neurosurg Rev. 2025 Jun 1;48(1):471. doi: 10.1007/s10143-025-03600-3.

 

Hormonal Health

The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial.

Atila C, Camerin SJ, Liechti ME, Christ-Crain M.Endocr Connect. 2025 Jun 1:EC-25-0254. doi: 10.1530/EC-25-0254. Online ahead of print.

Combined pituitary hormone deficiency with a novel GLI2 frameshift variant.

Matsuo Y, Adachi N, Mukai T, Kato S, Kato M, Tanaka H.Pediatr Int. 2025 Jan-Dec;67(1):e70082. doi: 10.1111/ped.70082.

 

 

 

Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

Sign up to get dedicated support:

Patients: Sign up for support | Recorlev® (levoketoconazole)

HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

Have more questions? Call for more support at 1-844-444-RCLV (7258)

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.